{"id":"W4205565447","doi":"10.1200/jco.2022.40.4_suppl.379","title":"Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":400,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Hazard ratio; Regimen; Confidence interval; Internal medicine; Clinical endpoint; Gastroenterology; Phases of clinical research; Randomized controlled trial; Surgery; Toxicity","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006777919,0.000210402,0.002610601,0.0002430958,0.0001042304,0.00001693485,0.0003790318,0.0001334367,0.0005463099],"category_scores_gemma":[0.0007880144,0.0001372612,0.000214265,0.0003087639,0.0002713582,0.0001539436,0.0002037723,0.0008883639,9.63464e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002596298,"about_ca_system_score_gemma":0.0009055207,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000780736,"about_ca_topic_score_gemma":0.0001953826,"domain_scores_codex":[0.9941031,0.001713835,0.002922915,0.0003045718,0.0006961649,0.0002594437],"domain_scores_gemma":[0.9953126,0.001700604,0.002106044,0.0002865259,0.0003966029,0.0001976304],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6023456,0.04839157,0.3114041,0.00001742889,0.0007456625,0.0004007767,0.0006822567,0.000008123126,0.00009048205,0.000001636704,0.0001980303,0.03571426],"study_design_scores_gemma":[0.7364944,0.203268,0.05392772,0.00005929298,0.0002946373,0.00006189654,0.0007492317,0.000602131,0.00006362613,0.00001653545,0.004350116,0.0001124366],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9941605,0.001334244,0.000006483774,0.001375198,0.0004744843,0.002401083,0.000008212901,0.000003901838,0.000235916],"genre_scores_gemma":[0.9971689,0.001118905,0.0002033917,0.001140569,0.0001177612,0.00006654422,0.00000630522,0.00002884811,0.000148796],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2574764,"threshold_uncertainty_score":0.598171,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1091740756274381,"score_gpt":0.4319048826952656,"score_spread":0.3227308070678275,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}